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 Introduction 
 Topical corticosteroids are used for a 
broad range of inflammatory skin condi-
tions. Side effects are rare and usually seen 
after prolonged application over months 
and years. The most frequent delayed side 
effects are skin atrophy, hypertrichosis, 
telangiectasia, steroid-induced acne and 
flare of perioral dermatitis. Immediate ad-
verse reactions to topical corticosteroids 
are usually brief and include a burning or 
itchy sensation. This usually does not lead 
to a discontinuation of the drug. Coombs 
type IV, delayed-type hypersensitivity re-
actions to corticosteroids are well known 
 [1] , whereas immediate-type hypersensi-
tivity reactions are very rare. However, the 
increasing number of patients with posi-
tive skin tests (prick and intradermal tests) 
for glucocorticoids indicates that imme-
diate-type hypersensitivity to glucocorti-
coids occurs  [2–4] . However, only in a few 
cases, a presence of specific immunoglob-
ulin E (IgE) in reaction to glucocorticoids 
was documented by the Radio-Allergo-
Sorbent-Test method  [5, 6] . Anaphylaxis 
and death have been reported in reaction 
to the systemic administration of cortico-
steroids  [7] . There are more than 100 pub-
lished reports of immediate hypersensitiv-
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 Abstract 
 We report a case of severe contact urticaria 
with systemic involvement resembling an 
anaphylactic reaction, following the appli-
cation of a topical corticosteroid. This was 
caused by hexylene glycol, an excipient in 
the formulation. Glycols are widely used in 
cosmetics, foods and topical and systemic 
drugs. In particular, glycols are present in 
many topical drugs used by dermatologists. 
To our knowledge, this is the first case in the 
literature of a potentially life-threatening 
immediate-type reaction in the context of a 
contact urticaria syndrome due to hexylene 
glycol. The classification of contact urticaria 
syndrome and the allergenic potential of 
glycols are reviewed. Dermatologists should 
be aware of the contact urticaria syndrome 
and of the increasing use of glycols in topical 
drug formulation in order to identify possi-
ble adverse reactions. 
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ity reactions occurring after oral and par-
enteral administration of corticosteroids 
 [5, 8] . Other than in delayed-type reac-
tions, no clear cross-reactive patterns be-
tween corticosteroid classes could be dem-
onstrated in immediate-type reactions  [9] . 
Only one report of anaphylaxis after the 
use of a topical corticosteroid cream could 
be found, and it was probably elicited by 
neomycin, which was present in the for-
mulation  [10] .
 Maibach and Johnson  [11] defined the 
contact urticaria syndrome in 1975; since 
then, numerous reports of the contact ur-
ticaria syndrome caused by a variety of 
compounds have been reported. The con-
tact urticaria syndrome can be described 
in two broad categories: nonimmunologic 
contact urticaria (type A) and immuno-
logic contact urticaria (type B). Examples 
of type A contact urticaria are the skin re-
action seen after exposure to jellyfish or 
nettles where a histamine release occurs 
without involving an immunologic pro-
cess. Type B contact urticaria is less com-
mon in clinical practice than nonimmu-
nologic contact urticaria. Type B contact 
urticaria is a Coombs type I hypersensi-
tivity reaction mediated by IgE antibodies 
specific to the eliciting substance. There-
fore, prior sensitization is required for this 
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type. Immunologic contact urticaria reac-
tions may typically spread beyond the site 
of contact and progress to generalized ur-
ticaria. If more severe, immunologic con-
tact urticaria may lead to anaphylactic 
shock. One such example is immunologic 
contact urticaria from natural rubber la-
tex.
 One year later, Odom and Maibach  [12] 
added a type C contact urticaria syndrome 
for those cases where neither an immuno-
logic nor a nonimmunologic mechanism 
had been identified  [13] . Although a hista-
mine release from mast cells is likely to be 
involved, it is unknown whether degranu-
lation is initiated immunologically or by 
direct action on the mast cells in those cas-
es  [14] . 
 We report a case of contact urticaria 
with systemic involvement resembling an 
anaphylactic reaction, following the appli-
cation of a topical corticosteroid. This was 
caused by hexylene glycol, an excipient in 
the formulation. The allergenic potential 
of glycols is reviewed. Written informed 
consent was obtained from the patient for 
the publication of this case report and ac-
companying images.
 Case Report  
 In January 2009, a 30-year-old, non-
atopic male patient presented to his gen-
eral practitioner, complaining of burning 
and dry skin on his back after a holiday in 
Brazil. He had neither a history of atopic 
diseases nor of contact hypersensitivity. 
He was prescribed topical mometasone
furoate cream (class III topical cortico-
steroid). The same night, he applied the 
cream on his back for the first time and 
after a few minutes felt a burning sensa-
tion, followed by angioedema (tongue and 
eyelids) and dyspnea after 45 min. A show-
er did not relieve the symptoms, and the 
patient presented to the emergency de-
partment where the physician document-
ed an urticarial skin reaction. Angioede-
ma was absent at this point. Two hours
later, the patient was dismissed in good 
condition, eupneic and with a completely 
abated skin rash after treatment with anti-
histamines. 
 One month later, skin prick tests were 
performed, showing no reaction to com-
mon allergens (pollen, house dust mites, 
pets, molds and latex). An open provoca-
tion test with mometasone furoate cream 
and ointment was performed in both cubi-
tal folds. After about 20 min, an urticarial 
rash appeared on both sides ( fig.  1 ). The 
common contents of both formulations, 
the cream and the ointment, are the fol-
lowing: mometasone furoate, hexylene 
glycol, purified water, phosphoric acid, 
propylene glycol stearate, white wax and 
white petrolatum.
 Skin prick tests with a topical cortico-
steroid patch series and Nasonex  (mo-
metasone furoate nasal spray) were nega-
tive. Skin prick tests with solid and fluid 
propylene glycol up to a 50% concentra-
tion were negative. Intracutaneous tests 
with Macrogol (polyethylene glycol or 
PEG) 400 and 6000 were also negative for 
concentrations up to 10%. Prick tests with 
white petrolatum, PEG DAB 8 and Physio-
gel  cream (pentylene glycol) were also 
negative ( table 1 ).  A positive reaction was 
present to pure hexylene glycol ( 1 99%; 
product ref. No. 112100-500G, CAS No. 
107-41-5; Sigma Aldrich Chemie GmbH, 
Buchs, Switzerland) in 1 and 10% concen-
trations by prick and rub tests ( fig. 2 ). Both 
were negative in 3 atopic and 2 nonatop-
ic controls. Similarly, Sebiprox shampoo 
(containing hexylene glycol) showed a ur-
ticarial skin reaction 20 min after open ap-
plication.
 Retrospectively, the patient remem-
bered having reacted in the past to a sham-
poo with a burning sensation on the head; 
however, he did not remember the brand 
name. Blood tests could not be performed 
due to aichmophobia (panic disorder re-
garding needles). The patient was advised 
to avoid hexylene-glycol-containing topi-
cal agents and shampoos and had no skin 
reaction ever since.
 Discussion 
 Glycols are alcohols containing two hy-
droxyl groups (diols) ( fig. 3 ). In medicine, 
PEG are the most widely used glycols. The 
numbers that are often included in the 
names of PEG indicate their average mo-
lecular weight, e.g. a PEG with an average 
molecular weight of approximately 400 Da 
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 Fig. 1. Contact urticaria 20 min after open application of Elocom  
ointment containing hexylene glycol. 
 Fig. 2. Contact urticaria after application of hexylene glycol 10%. 
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would be labeled PEG 400. With increas-
ing chain length, the preparation takes on 
the characteristics of a gel rather than a liq-
uid  [15] . The monomer, ethylene glycol, is 
notoriously toxic, being the solvent used
in an ‘elixir’ that killed over 100 people in 
1937  [15] . Toxicity has been reported for 
propylene glycol and PEG in parenteral 
administration, especially at high doses 
and in patients with renal impairment  [15] .
 PEG are the basis of a number of laxa-
tives, skin creams and sexual lubricants, 
frequently combined with glycerine. They 
are also used in a number of toothpastes as 
a dispersant; they bind water and help to 
retain a uniform distribution of gum in 
the toothpaste. When attached to various 
protein medications, e.g. PEG-interferon-
  , PEG slows the clearance of the thera-
peutic protein, allowing longer dosing in-
tervals. A conjugation of allergens with 
PEG often increases tolerogenity  [16–18] . 
This has been studied in immunotherapy 
 [18, 19] and more recently in drug develop-
ment  [20] . Paradoxically, PEG also have a 
potential to cause immediate-type hyper-
sensitivity reactions  [21–23] . Anaphylaxis, 
asthma, angioedema and urticaria have 
been described after the administration of 
oral PEG electrolyte lavage solutions  [24–
27] . Recently, anaphylaxis has also been
reported after tablets and intraarticular 
corticosteroid injections where PEG was 
used as a vehicle and an excipient, respec-
tively  [23, 28] . Phadia AB (Uppsala, Swe-
den) has recently developed a modified 
Table 1.  Name, concentration and application route of tested compounds
Compound Concentration Prick Intradermal
Amcinonide 0.1% negative nd
Hydrocortisone 1% negative nd
Triamcinolone acetonide 0.1% negative nd
Clobetasol-17-propionate 0.25% negative nd
Hydrocortisone-17-butyrate 0.1% negative nd
Betamethasone-17-valerate 0.12% negative nd
Budesonide 0.1% negative nd
Prednisolone 1% negative nd
Dexamethasone-21-phosphate disodium salt 1% negative nd
Tixocortol pivalate 1% negative nd
Propylene glycol 50% negative nd
Propylene glycol 25% negative nd
Propylene glycol 5% negative nd
Propylene glycol monostearate Tesal pure (solid) negative nd
Propylene glycol monostearate Nikkol pure (solid) negative nd
Propylene glycol monostearate Radiasurf pure (solid) negative nd
Propylene glycol monostearate Monosteol pure (solid) negative nd
Macrogol 400 1:10,000 of 10% nd negative
Macrogol 400 1:1,000 of 10% nd negative
Macrogol 400 1:100 of 10% nd negative
Macrogol 400 1:10 of 10% nd negative
Macrogol 400 10% nd negative
Macrogol 6000 1:10,000 of 10% nd negative
Macrogol 6000 1:1,000 of 10% nd negative
Macrogol 6000 1:100 of 10% nd negative
Macrogol 6000 1:10 of 10% nd negative
Macrogol 6000 10% nd negative
White wax pure negative nd
Nasonex (mometasone furoate) pure negative nd
Propylene glycol 5% negative nd
PEG cream 100% negative nd
Benzalkonium chloride 0.1% negative nd
Physiogel cream (pentylene glycol) pure negative nd
Sebiprox shampoo (containing hexylene glycol) pure positive nd
Elocom cream (containing hexylene glycol) pure positive nd
Hexylene glycol 1% positive nd
Hexylene glycol 10% positive nd
Positive = Urticarial reaction; nd = not done.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
4/
20
17
 1
0:
19
:4
0 
AM
 Contact Urticaria and Hexylene Glycol Dermatology 2010;220:238–242 241
version of the IgE and IgG antibody Im-
munoCAP assay for measuring antibodies 
to PEG. Seven patients were tested, all with 
negative specific IgE [Rosengren P., pers. 
commun., June 17, 2009].
 Propylene glycol (propane-1,2-diol) 
belongs to the vicinal diols having hy-
droxyl groups attached to adjacent atoms 
( fig.  3 ). Propylene glycol is used as a hu-
mectant food additive (E1520), as a mois-
turizer in cosmetics, food, toothpaste, 
mouth wash and tobacco products, as the 
main ingredient in deodorant sticks, as an 
antifreeze liquid and as a solvent in many 
pharmaceuticals including oral, injectable 
and topical formulations. Notably, in diaz-
epam, which is insoluble in water, propyl-
ene glycol is used as a solvent in its inject-
able form.
 Hexylene glycol (2-methyl-pentane-
2,4-diol) ( fig. 3 ) is mainly found in indus-
trial coatings (paints, lacquers and var-
nishes), in leather and textile processing as 
a moistening and softening agent, in anti-
freeze fluids, and in cosmetics and topical 
drugs (especially topical corticosteroids) 
at concentrations between 0.1 and 25%. 
Hexylene glycol is not as widely used as 
pentylene glycol in dermatological prod-
ucts  [29] , but is an ingredient in the cor-
ticosteroid preparation of Elocom (Sche-
ring-Plough). 
 Propylene glycol and hexylene glycol 
seem to act as sensitizers in contact allergy 
 [30–33] , i.e. delayed-type hypersensitivity 
reactions. In this context, cross-reactivity 
between propylene glycol and hexylene 
glycol has been described  [34] .
 The incidence of propylene glycol con-
tact allergy among patients with eczema 
has been evaluated to be greater than 2% 
 [35] . Contact dermatitis in reaction to pro-
pylene glycol in calcipotriene ointment 
and an ultrasonic gel  [36–39] , as well as in 
an antiviral cream (Zovirax  )  [40] , has 
been reported. Flares of contact dermatitis 
following the ingestion of foods contain-
ing propylene glycol have been noticed 
 [30] , and systemic contact dermatitis due 
to intravenous propylene glycol in diaze-
pam (Valium  ) in a patient sensitized to 
propylene glycol has been reported  [41] . 
One report described contact urticaria in 
reaction to a corticoid cream containing 
propylene glycol, the responsible chemi-
cal, however, was found to be polysorbate 
60, a mixture of stearate ester of sorbi-
tol and sorbitol anhydrides  [42] . Contact 
urticaria could not be observed in ex-
periments with open propylene glycol ap-
plication  [43] ; only one report describes 
nonimmunologic contact urticaria after 
topical propylene glycol application  [44] .
 Less is known about the incidence of 
hypersensitivity to hexylene glycol. In a 
first human study, 5 human subjects were 
given oral doses of 37 g of hexylene glycol 
daily for 24 days (estimated daily dosage: 
14–28 mg/kg body weight). No subjective 
symptoms that could be attributed to the 
intake of hexylene glycol were reported 
 [45] . First clues pointing to a sensitizing 
potential were seen in patch tests where 
hexylene glycol (10% aqueous) was tested 
in a group of 230 patients with occupation-
al dermatitis in the metallurgic industry. 
Nine patients had a positive patch test with 
hexylene glycol (3.9% of the total number 
tested)  [33] . An unclear reaction was re-
ported in 2.8% of 823 eczema patients test-
ed by patch tests with hexylene glycol at 
aqueous concentrations of 30 or 50% (48-
hour occlusion): they showed edema and 
erythema of the skin; the authors consid-
ered this indicative of an irritation rather 
than a contact allergy  [46] . In a further 
study, mometasone furoate 0.1% fatty 
cream (containing hexylene glycol, as in 
the present case) was applied twice weekly 
for 6 months. Among the 68 patients with 
atopic dermatitis, 4 showed adverse events 
related to the treatment: 2 showed follicu-
litis, 1 skin atrophy and 1 sensation of in-
creased warmth  [47] . It has not been men-
tioned whether the last was an urticarial 
skin reaction or not. Otherwise, so far no 
reports are present in the literature de-
scribing an immediate-type reaction to 
hexylene glycol.
 Our patient had a contact urticaria 
with systemic involvement following the 
application of a topical corticosteroid 
cream due to hexylene glycol which was 
present in the formulation. An open appli-
cation of diluted pure hexylene glycol elic-
ited contact urticaria, confirming its caus-
ative role. The systemic involvement and 
the possibility of a previous exposure and 
sensitization in our patient together with 
the negative tests in the controls favor an 
immunologically mediated process, but 
this could not be supported by specific IgE. 
Because no immunological test could be 
performed due to severe aichmophobia
in our patient, the pathogenetic process 
could not be further elucidated. Therefore, 
we consider this to be a type C contact ur-
ticaria syndrome. In our tests with other 
glycols, no cross-reactivity to propylene 
glycol or PEG could be detected. With 
strict avoidance of hexylene glycol contact, 
the patient remained free of symptoms.
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